Back to mobile site

Charles River Laboratories (CRL) Tops Q2 EPS by 7c, Updates Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. IBM
10. META

August 9, 2017 7:06 AM EDT

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $469.1 million versus the consensus estimate of $458.03 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.00-$5.15, versus the consensus of $5.10.

2017 GUIDANCE (from continuing operations)

REVISED

PRIOR

Revenue growth, reported 8.5% - 10.0% 7.5% - 9.0%
Less: Contribution from acquisitions (1) (~5.0% - 6.0%) (~5.0% - 6.0%)
Add: Effect of CDMO divestiture ~1.0% ~1.0%
Add: Negative effect of 53rd week in 2016 ~1.5% ~1.5%
Add: Negative effect of foreign exchange ~1.0% ~2.0% - 2.5%
Revenue growth, organic (2) 7.0% - 8.5% 7.0% - 8.5%
GAAP EPS estimate $4.18-$4.33 $4.18-$4.33
Amortization of intangible assets (3) ~$0.58 ~$0.58
Charges related to global efficiency initiatives (4) ~$0.02 ~$0.02
Acquisition/divestiture-related adjustments (5) ~$0.07 ~$0.07
Net impact of CDMO divestiture (6) ~$0.15 ~$0.15
Non-GAAP EPS estimate $5.00- $5.15 $5.00 - $5.15

Footnotes to Guidance Table

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings